TNGX Logo

Tango Therapeutics, Inc. (TNGX) 

NASDAQ$1.95
Market Cap
$210.81M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
318 of 924
Rank in Industry
184 of 527

TNGX Insider Trading Activity

TNGX Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$74,00025
Sells
$56,911,4783995

Related Transactions

Rothenberg Macedirector2$74,0000$0$74,000
Barry DouglasGeneral Counsel0$02$16,369$-16,369
Beckman DaniellaChief Financial Officer0$02$25,282$-25,282
Calhoun Lesley Anndirector0$01$36,039$-36,039
Crystal AdamSee Remarks0$02$43,866$-43,866
Weber BarbaraChief Executive Officer0$02$57,710$-57,710
MVA Investors, LLCSee remarks0$08$4.62M$-4.62M
EcoR1 Capital, LLC10 percent owner0$02$8.44M$-8.44M
Boxer Capital Management, LLCSee remarks0$04$20.12M$-20.12M
Third Rock Ventures IV, L.P.10 percent owner0$016$23.55M$-23.55M

About Tango Therapeutics, Inc.

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with â€¦

Insider Activity of Tango Therapeutics, Inc.

Over the last 12 months, insiders at Tango Therapeutics, Inc. have bought $74,000 and sold $56.91M worth of Tango Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at Tango Therapeutics, Inc. have bought $4.58M and sold $20.49M worth of stock each year.

Highest buying activity among insiders over the last 12 months: Rothenberg Mace (director) — $74,000.

The last purchase of 10,000 shares for transaction amount of $37,800 was made by Rothenberg Mace (director) on 2024‑11‑18.

List of Insider Buy and Sell Transactions, Tango Therapeutics, Inc.

2025-02-05SaleWeber BarbaraChief Executive Officer
9,013
0.0087%
$3.16$28,494-31.34%
2025-02-05SaleCrystal AdamSee Remarks
6,851
0.0066%
$3.16$21,659-31.34%
2025-02-05SaleBeckman DaniellaChief Financial Officer
3,948
0.0038%
$3.16$12,481-31.34%
2025-02-05SaleBarry DouglasGeneral Counsel
2,556
0.0025%
$3.16$8,081-31.34%
2025-02-04SaleWeber BarbaraChief Executive Officer
9,778
0.0093%
$2.99$29,217-23.52%
2025-02-04SaleCrystal AdamSee Remarks
7,432
0.0071%
$2.99$22,207-23.52%
2025-02-04SaleBeckman DaniellaChief Financial Officer
4,284
0.0041%
$2.99$12,801-23.52%
2025-02-04SaleBarry DouglasGeneral Counsel
2,774
0.0027%
$2.99$8,289-23.52%
2024-11-18PurchaseRothenberg Macedirector
10,000
0.0098%
$3.78$37,800-15.56%
2024-11-14PurchaseRothenberg Macedirector
10,000
0.0088%
$3.62$36,200-22.45%
2024-11-07SaleEcoR1 Capital, LLC10 percent owner
1.21M
1.1237%
$2.94$3.54M+7.60%
2024-11-06SaleEcoR1 Capital, LLC10 percent owner
1.49M
1.3103%
$3.28$4.9M-6.17%
2024-11-06SaleBoxer Capital Management, LLCSee remarks
3.08M
2.5882%
$3.14$9.67M-6.17%
2024-10-25SaleBoxer Capital Management, LLCSee remarks.
633,000
0.6113%
$6.87$4.35M-48.40%
2024-10-22SaleBoxer Capital Management, LLCSee remarks
250,000
0.2383%
$6.78$1.7M-53.61%
2024-10-21SaleBoxer Capital Management, LLCSee remarks
625,000
0.5752%
$7.05$4.41M-56.92%
2024-09-13SaleThird Rock Ventures IV, L.P.10 percent owner
67,400
0.0631%
$10.53$709,756-69.24%
2024-09-05SaleThird Rock Ventures IV, L.P.10 percent owner
75,000
0.0693%
$11.56$867,135-72.09%
2024-08-30SaleThird Rock Ventures IV, L.P.10 percent owner
175,000
0.1601%
$11.60$2.03M-71.85%
2024-08-27SaleThird Rock Ventures IV, L.P.10 percent owner
25,000
0.0236%
$11.55$288,665-70.61%
Total: 63
*Gray background shows transactions not older than one year

Insider Historical Profitability

29.82%
Rothenberg Macedirector
31250
0.0289%
$60,937.5020
Boxer Capital, LLC
8198642
7.5838%
$15.99M31+19.37%
Davis Aaron I.director
7123642
6.5894%
$13.89M30+36.79%
LEWIS JOSEPHdirector
7053642
6.5246%
$13.75M30+40.76%
BCTG Holdings, LLC10 percent owner
4488450
4.1518%
$8.75M11+7.42%
*Gray background shows insiders who have made transactions during last year

Historical Insider Profitability vs. Competitors

$21,574,635
88
2.81%
$211.87M
$7,150,333
87
-8.28%
$221.99M
$613,304,943
46
11.85%
$181.55M
$48,218,096
42
0.89%
$210.73M
$2,545,071
34
16.59%
$241.88M

TNGX Institutional Investors: Active Positions

Increased Positions86+64.66%41M+40.23%
Decreased Positions53-39.85%27M-26.97%
New Positions44New39MNew
Sold Out Positions27Sold Out11MSold Out
Total Postitions166+24.81%115M+13.26%

TNGX Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Trv Gp Iv, Llc$32,875.0015.61%16.86M00%2024-12-31
Tcg Crossover Management, Llc$20,935.009.94%10.74M+11MNew2024-12-31
Ecor1 Capital, Llc$20,730.009.84%10.63M-3M-20.25%2024-12-31
Boxer Capital Management, Llc$20,243.009.61%10.38M+10MNew2024-12-31
Boxer Capital, Llc$15,987.007.59%8.2M00%2024-09-30
Nextech Invest Ltd.$10,791.005.12%5.53M00%2024-12-31
Gilead Sciences, Inc.$9,466.004.5%4.85M+5MNew2024-12-31
Blackrock, Inc.$8,538.004.05%4.38M+17,168+0.39%2024-12-31
Farallon Capital Management Llc$7,800.003.7%4M+4MNew2024-12-31
Vanguard Group Inc$7,771.003.69%3.99M+339,922+9.32%2024-12-31

Financial Ratios

Summary
Comparison with Competitors

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
1.67SellsBuysStrong BuyBuyHoldSellStrong SellTNGXHighAverageLowSeries 4